WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the ...
The FDA has expanded the approval of Emend's indication for chemotherapy-induced nausea and vomiting. The FDA has approved Emend (aprepitant capsules) in combination with other antiemetic agents for ...
The FDA has approved the New Drug Application (NDA) for Emend (aprepitant; Merck) for oral suspension for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients aged ≥6 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback